Selepressin Citations: The Vasopressor & Inotrope Handbook

  1. Lövgren U, Johansson S, Jensen LS, Ekström C, Carlshaf A. Quantitative determination of peptide drug in human plasma samples at low pg/ml levels using coupled column liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2010 Nov 2;53(3):537-45. doi: 10.1016/j.jpba.2010.03.024. Epub 2010 Mar 27. PMID: 20456896.
    Link to (NOT FREE) Article
  2. Rehberg S, Ertmer C, Vincent JL, Morelli A, Schneider M, Lange M, Van Aken H, Traber DL, Westphal M. Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med. 2011 Jan;39(1):119-25. doi: 10.1097/CCM.0b013e3181fa3898. PMID: 20890184.
    Link to (NOT FREE) Article
  3. Rehberg S, Yamamoto Y, Sousse L, Bartha E, Jonkam C, Hasselbach AK, Traber LD, Cox RA, Westphal M, Enkhbaatar P, Traber DL. Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circ Physiol. 2012 Nov 15;303(10):H1245-54. doi: 10.1152/ajpheart.00390.2012. Epub 2012 Sep 7. PMID: 22961865; PMCID: PMC3517638.
    Link to Article
    Link to FULL FREE PDF
  4. Maybauer MO, Maybauer DM, Enkhbaatar P, Laporte R, Wiśniewska H, Traber LD, Lin C, Fan J, Hawkins HK, Cox RA, Wiśniewski K, Schteingart CD, Landry DW, Rivière PJ, Traber DL. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med. 2014 Jul;42(7):e525-e533. doi: 10.1097/CCM.0000000000000300. PMID: 24674922; PMCID: PMC4346299.
    Link to Article
    Link to FULL FREE PDF
  5. He X, Su F, Taccone FS, Laporte R, Kjølbye AL, Zhang J, Xie K, Moussa MD, Reinheimer TM, Vincent JL. A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock. Crit Care Med. 2016 Jan;44(1):23-31. doi: 10.1097/CCM.0000000000001380. PMID: 26496451; PMCID: PMC4684247.
    Link to Article
    Link to FULL FREE PDF
  6. Barabutis N, Marinova M, Solopov P, Uddin MA, Croston GE, Reinheimer TM, Catravas JD. Protective Mechanism of the Selective Vasopressin V1A Receptor Agonist Selepressin against Endothelial Barrier Dysfunction. J Pharmacol Exp Ther. 2020 Nov;375(2):286-295. doi: 10.1124/jpet.120.000146. Epub 2020 Sep 17. PMID: 32943478.
    Link to Article
    Link to FULL FREE PDF
  7. Milano SP, Boucheix OB, Reinheimer TM. Selepressin, a novel selective V1A receptor agonist: Effect on mesenteric flow and gastric mucosa perfusion in the endotoxemic rabbit. Peptides. 2020 Jul;129:170318. doi: 10.1016/j.peptides.2020.170318. Epub 2020 Apr 22. PMID: 32330539.
    Link to Article
    Link to FULL FREE PDF
  8. Russell JA, Vincent JL, Kjølbye AL, Olsson H, Blemings A, Spapen H, Carl P, Laterre PF, Grundemar L. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017 Aug 15;21(1):213. doi: 10.1186/s13054-017-1798-7. PMID: 28807037; PMCID: PMC5557574.
    Link to Article
    Link to FULL FREE PDF
  9. Laterre PF, Berry SM, Blemings A, Carlsen JE, François B, Graves T, Jacobsen K, Lewis RJ, Opal SM, Perner A, Pickkers P, Russell JA, Windeløv NA, Yealy DM, Asfar P, Bestle MH, Muller G, Bruel C, Brulé N, Decruyenaere J, Dive AM, Dugernier T, Krell K, Lefrant JY, Megarbane B, Mercier E, Mira JP, Quenot JP, Rasmussen BS, Thorsen-Meyer HC, Vander Laenen M, Vang ML, Vignon P, Vinatier I, Wichmann S, Wittebole X, Kjølbye AL, Angus DC; SEPSIS-ACT Investigators. Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. JAMA. 2019 Oct 15;322(15):1476-1485. doi: 10.1001/jama.2019.14607. Erratum in: JAMA. 2019 Nov 12;322(18):1830. PMID: 31577035; PMCID: PMC6802260.
    Link to Article and FULL FREE PDF
  10. Marks JA, Pascual JL. Selepressin in septic shock: sharpening the VASST effects of vasopressin?*. Crit Care Med. 2014 Jul;42(7):1747-8. doi: 10.1097/CCM.0000000000000420. PMID: 24933060.
    Link to (NOT FREE) Article
  11. Levy B, Fritz C, Tahon E, Jacquot A, Auchet T, Kimmoun A. Vasoplegia treatments: the past, the present, and the future. Crit Care. 2018 Feb 27;22(1):52. doi: 10.1186/s13054-018-1967-3. PMID: 29486781; PMCID: PMC6389278.
    Link to Article
    Link to FULL FREE PDF
  12. Stolk RF, van der Poll T, Angus DC, van der Hoeven JG, Pickkers P, Kox M. Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis. Am J Respir Crit Care Med. 2016 Sep 1;194(5):550-8. doi: 10.1164/rccm.201604-0862CP. PMID: 27398737.
    Link to Article
    Link to FULL FREE PDF
  13. Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaiotto FA, Pomerantzeff PM, Dallan LO, Franco RA, Nakamura RE, Lisboa LA, de Almeida JP, Gerent AM, Souza DH, Gaiane MA, Fukushima JT, Park CL, Zambolim C, Rocha Ferreira GS, Strabelli TM, Fernandes FL, Camara L, Zeferino S, Santos VG, Piccioni MA, Jatene FB, Costa Auler JO Jr, Filho RK. Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial. Anesthesiology. 2017 Jan;126(1):85-93. doi: 10.1097/ALN.0000000000001434. PMID: 27841822.
    Link to Article
    Link to FULL FREE PDF